1. Home
  2. Products
  3. Customized ADCs
  4. EpCAM
  5. Anti-EpCAM-hydrazone-Doxorubicin ADC-2

Anti-EpCAM-hydrazone-Doxorubicin ADC-2 (CAT#: ADC-W-581)

This ADC product is comprised of an anti-EPCAM monoclonal antibody (MOC31) conjugated via a hydrazone linker to Doxorubicin. The Doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Doxorubicin binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • EpCAM
  • Alternative Names
  • EPCAM; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1; epithelial glycoprotein 314; human epithelial glycoprotein-2; cell surface glycoprotein Trop-1; adenocarcinoma-associated an
  • Target Entrez Gene ID
  • 4072
  • Overview
  • This gene encodes a carcinoma-associated antigen and is a member of a family that includes at least two type I membrane proteins. This antigen is expressed on most normal epithelial cells and gastrointestinal carcinomas and functions as a homotypic calcium-independent cell adhesion molecule. The antigen is being used as a target for immunotherapy treatment of human carcinomas. Mutations in this gene result in congenital tufting enteropathy.
  • Overview
  • Anti-EpCAM Antibody, MOC31
  • Generic name
  • MOC31
  • Species Reactivity
  • Human
  • Name
  • acid-cleavable hydrazone linker
  • Description
  • Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
  • Name
  • doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-581. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Payload
CAT# Product Name Linker Payload
ADC-W-1098 Anti-EPCAM (Edrecolomab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-1084 Anti-EPCAM (Tucotuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-1079 Anti-EPCAM (Citatuzumab bogatox)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1082 Anti-EPCAM (Tucotuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-1097 Anti-EPCAM (Edrecolomab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
CAT# Product Name Linker Payload
ADC-W-479 Anti-CD74-SMCC-Dox ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-340 Anti-TNFRSF8-DIBO-doxorubicin ADC-12 DIBO (dibenzylcyclooctynol) doxorubicin
ADC-W-602 Anti-FOLR1-S-S-Dox ADC disulfide (“S-S”) linker doxorubicin
ADC-W-423 Anti-FUT3-hydrazone-doxorubicin ADC hydrazone doxorubicin
ADC-W-463 Anti-FUT3-Mc-Dox ADC Mc (maleimidocaproyl) Doxorubicin

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.